End the duopoly

Extrapyramidal Symptoms in Schizophrenia Associated With Higher Healthcare Costs


Patients with EPS had significantly higher rates of all-cause hospitalizations, schizophrenia-related hospitalizations, and schizophrenia-related emergency department visits. The following article is a part of conference coverage from Psych Congress 2020 Virtual Experience , held virtually from September 10 to 13, 2020. The team at Psychiatry Advisor will be reporting on the latest news and research conducted by leading experts in psychiatry. Check back for more from the Psych Congress 2020 . Extrapyramidal symptoms (EPS) that developed in patients with schizophrenia after initiating treatment with an atypical antipsychotic were associated with increased healthcare resources and costs, according to findings presented at Psych Congress 2020, held virtually from September 10 to 13, 2020.

Researchers conducted a retrospective, administrative claims-based analysis of Medicaid patients newly initiating treatment with atypical antipsychotics to determine the economic burden of EPS in schizophrenia. The MarketScan Multi-State Medicaid database was used to identify patients with schizophrenia who started treatment with atypical antipsychotics without previous incidence of EPS from January 1, 2012, through December 31, 2018.

EPS were defined using diagnoses and medications from the International Classification of Diseases , Ninth and Tenth revisions. The researchers assessed demographics, clinical characteristics, healthcare resource use, and costs during a 12-month period following […]

read more here —> www.psychiatryadvisor.com

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More